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Chronic daily headache refers to the daily or almost daily
occurrence of headache. However, not all daily or almost
daily headaches fall under this denominator, as is the case
with the daily or almost daily headaches of (chronic) cluster
headache and (chronic) paroxysmal hemicrania. These con-
ditions are referred to as paroxysmal daily headaches, in
which the headaches occur in well-defined attack patterns.
In cluster headache, the attack pattern is that of headaches
occurring once or twice per day, lasting for one-half to 2
hours; in paroxysmal hemicrania, it is that of headaches
occurring 5–15 times per day, lasting for 10–30 minutes.
Of the non-paroxysmal daily headaches, hemicrania
continua is a condition that does not fall under the denomi-
nator of chronic daily headache either. However, it is dis-
cussed in this review because it is difficult, if not impossi-
ble, to distinguish from chronic daily headache on the basis
of its presentation alone. It differs from chronic daily
headache in the somewhat more consistent and less variable
intensity of the headache and in the absolute response to
preventive treatment with indomethacin.
Presentation
In a study of 258 patients from my private headache practice
with chronic daily headache, defined as headaches occurring
at least 5 days per week for at least 1 year, my colleagues
and I characterized the presentation of the headache condi-
tion [1]. We excluded only those patients with daily
headaches who described well-established paroxysmal
headache syndromes, in order to capture as much of the clin-
ical features of the condition as possible. Of the 258
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Abstract Chronic daily headache
relates to the daily or almost daily
occurrence of headache in a non-
paroxysmal pattern. In this review, I
discuss the presentation, develop-
ment, outcome, and treatment of
chronic daily headache. In the con-
text of the development of chronic
daily headache, a headache continu-
um is presented along with its under-
lying pathophysiology. The treatment
section covers rebound headache,
analgesic and vasoconstrictor with-
drawal, and the use of long-acting
opioids in intractable patients. The
review concludes with a discussion
of hemicrania continua, an
indomethacin-responsive headache
syndrome.
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patients, 19% were men and 81% women; their average age
at the time of consultation was 42 years. The distribution of
the age at onset of (any) headache for the men and women
separately is shown in Fig. 1: 77% of all patients (69% of
men and 79% of women) experienced the onset of headache
before the age of 30 years. The onset of headache occurred
in the second decade of life in 36% of the women, as
opposed to 24% of the men. The peak of headache onset in
the second decade in women is indicative of the importance
of the menstrual cycle in the development of headache in
women.
With regard to diurnal pattern, the daily headaches were
present on awakening or came on in the course of the morn-
ing in 79% of the patients, came on in the afternoon or
evening in 6%, and had a variable time of onset in 15% (Fig.
2). In 25%, the headaches were worst on awakening or in the
course of the morning; in 53% they were worst in the after-
noon or evening, and in 22% they were worst at a variable
time of the day. The results agree with my clinical observa-
tion that daily headaches come in two distinct diurnal pat-
terns. The most common pattern is that in which the
headaches gradually increase in intensity as the day pro-
gresses, to be worst in the afternoon or evening. According
to the results of the study, this is the pattern in more than half
of the patients with chronic daily headache. The less com-
mon pattern, which I refer to as the “reversed diurnal pat-
tern”, is that in which the headaches are worst on awakening
in the morning and gradually improve as the day progresses.
This was the case in one-quarter of the patients while in the
remaining quarter, the diurnal course of the headaches was
variable.
The reversed diurnal pattern is associated with the
most frequent nighttime awakenings with headache. In
the study, nocturnal awakening by headache occurred at
least once per week in 36% of the patients. Of the patients
who were woken up by headache at least once per week,
48% experienced the worst headache on awakening or in
the course of the morning, as opposed to 22% of the
patients who were woken up by headache less than once
per week.
Fig. 1 Age at onset of (any)
headache, by gender (n=251).
(From [1] with permission)
Fig. 2 Diurnal pattern of the daily
headaches (n=214). (From [1]
with permission)113
With regard to associated symptoms, the daily headaches
were at least twice per week associated with nausea in 35%
and with vomiting in 9%. With regard to the laterality of the
daily headaches, 36% were unilateral, 50% bilateral, and
14% either unilateral or bilateral. The unilateral headaches
had a fixed lateralization in 83% and alternated between the
left and right sides in 17%. The aggravating factors of the
daily headaches are shown in Table 1. Apart from light and
noise, most common were physical activity, bending over,
stress or tension, and menstruation.
Overall, 94% of the patients experienced severe
headaches in addition to the daily headaches (Fig. 3).
Twenty-six percent of the patients experienced severe
headaches more than 15 days per month, while the majority
(63%) experienced severe headaches 10 days per month or
less. The results suggest that the majority of the patients with
chronic daily headache who seek specialty care for their
headaches do not have chronic tension-type headache. They
have chronic tension-type headache combined with migraine
or, as I prefer to call it, tension-type vascular headache. This
conclusion is based on the view that, with regard to clinical
presentation, intensity is the predominant distinguishing fea-
ture between migraine and tension-type headache.
With regard to laterality, the severe headaches were uni-
lateral in 43%, bilateral in 42%, and either unilateral or
bilateral in 15%. The unilateral headaches had a fixed later-
alization in 79% and alternated between the left and right
sides in 21%. One would expect the severe headaches to be
lateralized more often than the daily headaches, but this was
not the case. With regard to associated symptoms, the severe
headaches were at least twice per month associated with
nausea in 76% and with vomiting in 38%.
In the development of chronic daily headache, medica-
tion intake is considered to play an important role, in partic-
ular the intake of analgesic and vasoconstrictor medications
[2]. Awidely used vasoconstrictor for the abortive treatment
of headache is caffeine, in beverages, especially coffee, but
also in prescription and non-prescription medications.
Therefore, we measured the caffeine intake of our patients
with chronic daily headache, by looking at their coffee and
medication intakes. A cup of coffee was considered to con-
tain 100 mg caffeine. We found that 43% of the patients used
less than 100 mg caffeine per day, 35% between 100 and
300 mg, and 22% more than 300 mg. The average caffeine
intake was 170 mg per day, which is approximately the
equivalent of two cups of coffee. This is less than what was
found in the population of Sydney, Australia, where the
average caffeine intake was 240 mg per day, with 30% con-
suming more than 300 mg [3].
With regard to analgesic use, we only considered the
non-opioid medications because opioids were hardly used
by the patients for the treatment of headaches. Furthermore,
Fig. 3 Frequency of severe headaches
in days per month (n=197). (From [1]
with permission)







Stress or tension 29
Menstruationa 28
Alcohol 20
Coughing or sneezing 15
Foods or drinks 13
Lack of sleep 12




a For women only; n=208114
of the barbiturate-containing medications, we did not take
into account the barbiturate component because it is not
strictly an analgesic. With these limitations, we found that
26% of the patients used less than 500 mg aspirin-equiva-
lents per day and 48% less than 1500 mg. The average anal-
gesic intake was 1860 mg aspirin-equivalents per day, which
is roughly the same as that found by Mathew et al. [4] in
their patients with chronic daily headache. However, it is
about half that reported by Kudrow [5] in his landmark
paper on the paradoxical effects of frequent analgesic use on
headache.
The preceding information on caffeine and analgesic
intake only serves to describe, from this perspective, the
patient population studied. Conclusions with regard to a
possible causative role in the development of chronic daily
headache can only be derived from prospective, discontinu-
ation studies.
Development
Of the 230 patients in the study for whom information was
available regarding the onset of headaches, 22% experi-
enced daily headaches from the onset [6]. This can be called
primary  chronic daily headache, in the same way as we
speak of primary and secondary chronic cluster headache.
The remaining 78% initially experienced intermittent
headaches, that is, they had secondary  chronic daily
headache. The distribution of the age at onset of the
headaches in those 50 patients with daily headaches from
the onset (primary chronic daily headache) is shown in Fig.
4. Sixty-six percent of the patients experienced the onset of
the daily headaches between the ages of 10 and 39 years.
Of the 179 patients with daily headaches but who initial-
ly had intermittent headaches, that is, of those with sec-
ondary chronic daily headache, 34 (19%) experienced an
abrupt onset of the daily headaches and 145 (81%) a grad-
ual onset. The distribution of the age at onset of the daily
headaches in those patients with abrupt-onset secondary
chronic daily headache is shown in Fig. 5. There is no dif-
ference between this distribution and that of the patients
with primary chronic daily headache, as shown in Fig. 4.
The circumstances related to the onset of the daily
headaches in the patients with primary chronic daily
headache and in those with abrupt-onset secondary chron-
ic daily headache are shown in Table 2. The table also
shows the circumstances of daily headache onset for the
two groups combined, as there was no difference in distri-
bution of the circumstances between the two groups. The
most common circumstance of daily headache onset in the
two groups combined was head, neck, or back injury,
caused by a motor-vehicle accident in 61%. Flu-like ill-
ness/sinusitis and medical illness/surgical procedure fol-
low it as causes of daily headache onset. Examples of
medical illness associated with the (abrupt) onset of
chronic daily headache are colitis, fibromyalgia, vertigo,
encephalitis, and meningitis.
There were also no differences between the patients with
primary chronic daily headache and those with abrupt-onset
secondary chronic daily headache with regard to the follow-
ing features: gender distribution, time of daily headache
occurrence, worst headache time daily, nocturnal awaken-
ing, laterality of the daily headaches, occurrence and fre-
quency of severe headaches, laterality of the severe
headaches, and parental occurrence of headache. The only
difference between the two groups was the association of the
daily and severe headaches with nausea. Nausea was more
common in the patients with abrupt-onset secondary chron-
ic daily headache than in those with primary chronic daily
headache. The difference is probably due to the fact that
57% of the patients in the abrupt-onset group had a history
of severe headaches, which tend to be associated with gas-
trointestinal symptoms.
Fig. 4 Age at onset of daily
headache, in the patients with pri-
mary chronic daily headache
(n=50). (From [6] with permission)115
The distribution of the age at onset of the daily
headaches in those patients with gradual-onset secondary
chronic daily headache is shown in Fig. 6. Seventy-eight
percent of the patients experienced the onset of daily
headaches between the ages of 20 and 49 years. The distrib-
ution of the age at onset of the initial, intermittent headaches
in this group is shown in Fig. 7. The two figures are com-
bined in Fig. 8, which shows the distribution of the age at
initial and daily headache onset in the patients with gradual-
onset secondary chronic daily headache. The average dura-
tion of the transition of the headaches from intermittent to
daily was 11 years, which is reflected in the figure by the
separation of the two distributions by approximately a
decade.
With regard to parental occurrence, headache in the
father or mother was more common in the patients with
gradual-onset secondary chronic daily headache than in the
combined group of those with primary chronic daily
headache and abrupt-onset secondary chronic daily
headache (69% vs. 45%). This observation is interesting
because conditions that develop abruptly generally have less
of a genetic involvement than do those that develop gradu-
Fig. 6 Age at onset of daily
headache, in the patients with
gradual-onset secondary chronic
daily headache (n=106). (From [6]
with permission)
Fig. 5 Age at onset of (daily)
headache, in the patients with
abrupt-onset secondary chronic
daily headache (n=32). (From [6]
with permission)
Table 2 Circumstances of (abrupt) onset of the daily headaches. Values are percent of patients. (From [6] with permission)
Primary chronic  Abrupt-onset secondary  Combined 
daily headache (n=51) chronic daily headache (n=34) group (n=85)
Head, neck, or back injury 25 29 27
Flu-like illness or sinusitis 12 18 14
Medical illness or surgical procedure 14 15 14
Miscellaneous 18 12 15
No apparent reason 31 26 30116
ally. On the basis of the information gathered on parental
headache occurrence, this also seems to be the case in
chronic daily headache.
With regard to the intensity of the initial headaches, in
the 145 patients with gradual-onset secondary chronic
daily headache, the headaches were mild in 33% and
severe in 67% (Table 3) [7]. The mild headaches were
associated with nausea in 25% and vomiting in 0%, as
opposed to the severe headaches, which were associated
with nausea in 84% and vomiting in 72%. With regard to
the frequency of the initial headaches, there was no differ-
ence between the mild and severe headaches: The mild
headaches occurred less than twice per week in 88% and
the severe headaches in 91%.
Table 4 shows the features of the daily headaches sepa-
rately for those patients whose initial headaches were mild
and for those whose initial headaches were severe. There
were no differences between the two groups with regard to
any of the features studied. The two groups also did not dif-
fer significantly from each other with regard to the age at
onset of the (initial) headaches (Fig. 9). 
Fig. 7 Age at onset of initial
headache, in the patients with grad-
ual-onset secondary chronic daily
headache (n=145). (From [6] with
permission)
Fig. 8 Age at onset of initial and
daily headache, in the patients
with gradual-onset secondary
chronic daily headache (n=145
and 106, respectively). (From [6]
with permission)
Table 3 Features of the initial headaches in the patients with grad-
ual-onset secondary chronic daily headache
Mild Severe
Headache intensity (n=112) 33% 67%
Associated symptoms n=12 n=61
Nausea 25% 84%
Vomiting 0% 72%
Headache frequency n=25 n=60
≤4 per month 60% 73%
5–9 per month 28% 18%
10–19 per month 8% 7%
≥20 per month 4% 2%117
From a classification perspective, does it make sense to
distinguish between primary and secondary chronic daily
headaches as we did and, within the latter group, between
abrupt and gradual onset? Judging from the age at onset of the
daily headaches, gender distribution, headache presentation,
circumstances of headache onset, and parental headache
occurrence, there does not seem to be a reason for the dis-
tinction between primary chronic daily headache and sec-
ondary chronic daily headache with abrupt onset. The two
groups should probably be considered as having one and the
same chronic daily headache condition, which could be
referred to as abrupt-onset chronic daily headache, represent-
Table 4 Features of the daily headaches in the patients with gradual-onset secondary chronic daily headache, according to the initial inten-
sity of the  headaches. (From [11] with permission)
Mild Severe
Gender n=37 n=75
Women, (%) 84 80
Men, (%) 16 20
Diurnal headache patterna
Time of headache onset n=36 n=75
Awakening or morning, (%) 83 69
Afternoon or evening, (%) 3 9
Variable, (%) 14 22
Time of worst headache n=33 n=67
Awakening or morning, (%) 39 18
Afternoon or evening, (%) 39 55
Variable, (%) 22 27
Nocturnal headache awakening n=34 n=70
At least once/week, (%) 29 39
Associated symptoms n=37 n=70
Nausea, (%) 41 43
Vomiting, (%) 8 13
Laterality n=37 n=75
Unilateral, (%) 32 48
Bilateral, (%) 57 39
Uni/bilateral, (%) 11 13
Occurrence of severe headaches, (%) 97 (n=36) 96 (n=74)
Associated symptoms of severe headaches n=36 n=69
Nausea, (%) 75 87
Vomiting, (%) 37 48
Frequency of the severe headaches n=29 n=62
1–5 days/month, (%) 35 31
6–10 days/month, (%) 31 31
11–15 days/month, (%) 14 19
16–20 days/month, (%) 3 8
>20 days/month, (%) 17 11
Laterality of the severe headaches n=35 n=70
Unilateral, (%) 43 53
Bilateral, (%) 49 33
Unilateral or bilateral, (%) 8 14118
ing 37% of our study group. However, this group should
probably be distinguished from the one with chronic daily
headache with gradual onset because of the very different
development of the daily headaches and the difference in
parental headache occurrence. The latter group could be
referred to as gradual-onset chronic daily headache. Future
studies will have to decide whether the distinction is mean-
ingful in terms of predicting treatment and/or outcome.
Headache continuum
The previously described findings with regard to the devel-
opment of chronic daily headache support the concept of
headache continuum as I originally proposed (Fig. 10)
[8–11]. The headache continuum includes episodic and
chronic tension-type headache, migraine headache, and ten-
sion-type vascular headache. Tension-type headache and
migraine are the two most common headache presentations.
Episodic tension-type headache is almost universally expe-
rienced, while migraine headaches affect 10%–15% of the
population. The major clinical distinction between the two,
in my opinion and as mentioned previously, is the intensity
of the headaches. Headache intensity is traditionally divided
into three categories, that is, mild, moderate, and severe,
depending on the extent to which the headache affects the
ability to function. Amild headache does not affect the abil-
ity to function, a moderate headache affects the ability to
function but does not necessitate bed rest, and a severe
headache is incapacitating and requires bed rest. Tension-
type headaches are typically mild or moderate in intensity
while migraine headaches tend to be moderate or severe.
Related to the (peripheral) mechanisms involved in
causing the pain, the migraine headache is localized while
the tension-type headache is more diffuse in location. The
migraine headache is localized not only to one side of the
head but within the side of the head, to areas such as the
temple or eye. The pain tends to be throbbing or sharp,
steady in nature, while the pain of tension-type headache
is more dull and steady. Also related to the mechanisms
involved in causing the pain, the migraine headache is
affected by movement and activity, which is not typically
the case with tension-type headache. The migraine
headache often develops during the night and is present on
awakening in the morning or wakes the patient up out of
sleep at night, usually between 4 and 6 AM. Episodic ten-
sion-type headache, on the other hand, generally comes on
during the day, often in the late afternoon, that is, between
4 and 6 PM. The episodic tension-type headache lasts for
a couple of hours, whereas the migraine headache lasts
from part of a day to several days. Related to the general-
ly low intensity of the pain, tension-type headache has
few, if any, symptoms associated with it and when symp-
toms are present, they are mild in intensity. The migraine
headache, on the other hand, has intense associated symp-
toms related to the generally high intensity of the pain.
Almost universally present in migraine are photophobia
and phonophobia; however, nausea is also common and
with the most intense migraine headaches, vomiting
occurs as well.
There is ongoing debate with regard to the mechanisms
involved in causing the pain of tension-type headache and
migraine. It is my belief that peripheral mechanisms are
important in both headache presentations, although the pre-
sent thinking is more oriented toward central mechanisms,
including central sensitization. Central sensitization relates
to the lowering of the activation threshold of central, senso-
ry neurons to peripheral stimulation. The mechanism by
which this occurs, if it does, is not known.
Fig. 9 Age at onset of headache, in
the patients with gradual-onset sec-
ondary chronic daily headache, sep-
arately for those with initially mild
headaches (n=37) and those with
initially severe headaches (n=75).
(From [6] with permission)119
In tension-type headache, the peripheral mechanism is
that of sustained contraction of the craniocervical muscles;
in migraine headache it is that of extracranial arterial
vasodilation. The arterial vasodilation in migraine acti-
vates a secondary mechanism, which is known as neuro-
genic inflammation. Stretching of the nerve fibers
involved in pain transmission (C and Aδ) surrounding the
blood vessels causes the neurogenic inflammation. The
stretching causes the nerve fibers to depolarize, which, on
the one hand, generates the action potentials that are trans-
mitted to the central nervous system. On the other hand, it
causes the release of inflammatory chemicals into the
peripheral tissues, such as substance P, calcitonin gene-
related peptide, and neurokinin A. The inflammatory
chemicals act to further dilate the arteries and also lower
the pain threshold locally in the peripheral tissues. Thus, a
vicious cycle is created in which vasodilation causes
inflammation that, in turn, accentuates the vasodilation and
renders it extremely painful.
When headaches occur regularly, they lead, through an
involuntary reflex mechanism, to progressive tightening of
the craniocervical muscles. The greater intensity of the pain
makes this effect more pronounced in migraine than in ten-
sion-type headache. Hence, temporal and cervical elec-
tromyographical activity is higher in migraine patients than
it is in those with tension headache [12]. Likely contributing
factors to the process of tightening of the craniocervical
muscles are treatment of tension-type headaches with anal-
gesics (as opposed to efforts to relax the muscles) and lack
of effective abortive treatment in migraine.
In tension-type headache, the progressive increase in
tightness of the craniocervical muscles leads, over time, to
an increase in frequency of the headaches. It also leads to
a progressive earlier occurrence of the headaches during
the day. Ultimately, a daily or almost daily headache con-
dition develops in which the headaches are present on
awakening or come on shortly after getting up. As long as
the headaches remain mild or moderate in intensity, the
condition can be referred to as chronic tension-type
headache. However, once the headaches have taken up all
available time, they tend to increase in intensity to create
“migraine headaches”. The condition is then referred to as
migraine with chronic tension-type headache. However, a
better term would be tension-type vascular headache,
emphasizing the existence of one single headache condi-
tion, rather than suggesting the presence of two separate
conditions.
When the regular occurrence of migraine headaches
leads to a progressive increase in tightness of the cranio-
cervical muscles, a gradual increase in frequency of the
headaches occurs, as well as a progressive interposition of
the migraine headaches with tension-type headaches. The
increase in frequency of the migraine headaches, I pro-
pose, is due to the fact that the muscle tightness, in and by
itself, becomes a trigger of migraine headaches. As the
muscles become tighter, they begin to interfere mechani-
cally with their own circulation, creating a stimulus for
dilation of the feeding arteries. One such feeding artery is
the frontal branch of the superficial temporal artery,
which overlies the powerful temporalis muscle. This is
also the artery that is involved, preferentially, in the
process of migrainous vasodilation, causing the throbbing
or sharp, steady pain in the temple so characteristic of the
condition [13]. Ultimately, the migraine and tension-type
headaches merge into daily or almost daily headaches,
with frequently occurring migraine headaches. A condi-
tion is, thus, created that is identical to what has been
described previously as migraine with chronic tension-
type headache or tension-type vascular headache.
However, the difference is that here it developed out of
migraine (“transformed” or “chronic migraine”), while
the condition described before developed, through chron-
ic tension-type headache, out of episodic tension-type
headache.
Fig. 10 The continuum of
headache syndromes, which
includes episodic and chron-
ic tension-type headache,
migraine headache, and ten-
sion-type vascular headache120
Outcome
Of the 145 patients in our study with gradual-onset (sec-
ondary) chronic daily headache, we were able to contact 91
(63%) [7]. Seven patients refused to participate in the follow-
up telephone interview, and eleven no longer remembered the
nature of their initial headaches. One patient was excluded
from the analysis because of the absence of headaches at the
time of contact and three patients because of missing data.
The remaining 69 patients (77%) were able to provide ade-
quate information to classify their initial and present
headaches as tension-type headache or migraine according to
International Headache Society (IHS) criteria [14].
Of the 69 patients, 23 (33%) still had daily headaches,
while the remaining 46 (67%) again experienced intermit-
tent headaches. Of the latter 46 patients, the initial
headaches were classified as migraine in 39 (85%) and ten-
sion-type in 7 (15%) (Table 5). Their present headaches
were classified as migraine in 34 (74%) and tension-type in
12 (26%). Thus, over time a slight shift had occurred from
migraine to tension-type headache. Similar shifts over time
from migraine to tension-type headache have been observed
in children and adolescents by Dooley and Bagnell [15] and
Guidetti and Galli [16]. Dooley and Bagnell conducted a 10-
year follow-up study of 77 children and adolescents. At the
initial evaluation, they found 83% to have migraine and
17% tension-type headache, while at follow-up these num-
bers were 60% and 40%, respectively [15]. Guidetti and
Galli conducted an 8-year follow-up study of a random sam-
ple of 100 children and adolescents, out of a total group of
240 with migraine or tension-type headache, diagnosed
according to IHS criteria. At the initial evaluation, they
found 79% of the patients to have migraine and 21% episod-
ic tension-type headache, while at follow-up these numbers
were 55% and 45%, respectively [16].
However, the question that we wanted to address in our
study was not whether the patients with intermittent
headaches had improved in comparison to their initial
headaches, but whether the patients with gradual-onset chron-
ic daily headache reverted back to their initial headache con-
dition, once the headaches had become intermittent again. In
the study, of the 39 patients whose initial headaches were
classified as migraine, 30 (77%) also had migraine at follow-
up and nine (23%) had tension-type headache (Table 5). Of
the seven patients whose initial headaches were classified as
tension-type, three (43%) had tension-type headache at fol-
low-up and four (57%) had migraine. Therefore, it seems that
after going through daily headaches, migraine patients as a
rule revert back to migraine, although some find their
headaches changed to episodic tension-type headache.
However, the situation is different for those patients who ini-
tially had episodic tension-type headache. They seem to come
out worse after having experienced daily headaches, with
some left with headaches that have features and associated
symptoms categorized as migraine in the IHS classification.
While we found that 57% of our patients who initially had
episodic tension-type headaches had evolved into migraine,
Dooley and Bagnell [15] found this to be the case in 11% of
their children and adolescents, and Guidetti and Galli [16]
observed this in 25%. Apart from the age difference, howev-
er, there is also the fact that in our study all patients had pro-
gressed, at one point in time, to daily headaches, which was
not the case in the pediatric studies. In addition, the number
of patients in the tension-type headache group in our study is
small, making it difficult to draw a reliable conclusion.
Treatment
The first step in the treatment of chronic daily headache is
the accurate establishment of the use of analgesic and vaso-
constrictor medications, prescription and non-prescription.
It is important to establish their use in terms of the number
of tablets or capsules taken per day and the number of days
of use per week or month. Patients tend to be notoriously
vague about their intake of medications that they take as
needed only. They also often have to be reminded specifi-
cally with regard to the use of non-prescription medications.
Once the exact intake of analgesic and vasoconstrictor med-
ications has been established, it should be determined
whether there is “overuse”. Overuse is defined as medica-
tion intake for headache that is detrimental rather than ben-
eficial to the headaches. It is use that promotes the occur-
rence of headaches long-term rather than providing
headache relief. Analgesic and vasoconstrictor medications
promote headache if they are taken at time intervals shorter
than their duration of action, which means that frequency of
intake is more important than quantity. Hence, when these
medications are allowed to accumulate in the system, they
bring on headache when their effect wears off, a phenome-
non that has become known as “rebound”.
Table 5 Present and initial headaches in the 46 patients (36 women
and 10 men) who initially had intermittent headaches, developed
daily headaches through a gradual transition, and again have inter-
mittent headaches. Values are numbers of patients
Initial headaches Present headaches Total
Migraine Tension-type
Migraine 30 393 9
Tension-type 34 33 37
Total 34 12 46121
Rebound headache generally occurs when analgesic or
vasoconstrictor medications are taken more often than 2
days per week on the average. This is particularly true for
caffeine-containing medications because of the prolonged
vasoconstrictor effect of caffeine, which can last up to 60
hours. A higher frequency of intake of analgesic or vaso-
constrictor medications can be allowed for simple anal-
gesics and the shorter-acting triptans, such as sumatriptan. A
lower frequency of intake has to be considered with the
longer-acting ergots, ergotamine and dihydroergotamine.
However, it has to be kept in mind that the “rebound thresh-
old” has not been determined for any medication or group of
medications. Also, the diagnosis of rebound headache can
only be made retrospectively, after withdrawal from anal-
gesic or vasoconstrictor medications has been accomplished
and improvement of headaches has occurred. Asuspicion of
rebound headache can be based not only on the frequency of
medication intake but also on increased medication usage
over time, with decreasing efficacy (Fig. 11). The decreas-
ing efficacy is often attributed to the development of toler-
ance but, in my opinion, it is more a manifestation of wors-
ening of the headaches and an indication that use has
become overuse.
If it is suspected that medication overuse and rebound
headache are present, this needs to be addressed next.
However, it can only be addressed after the patient has been
given insight into the situation. With regard to vasoconstric-
tor medications, reference can be made to the vascular
mechanism of headache. The vascular mechanism is antag-
onized by the vasoconstrictor medications, resulting in
rebound vasodilation and headache recurrence when the
vasoconstrictor effect wears off. Analgesic medications only
address the pain of the headache and not the underlying
mechanisms. Consequently – and as with symptomatic treat-
ment in general – the underlying mechanisms deteriorate,
resulting in worsening of the headaches.
The withdrawal of analgesic and vasoconstrictor med-
ications is generally best accomplished abruptly. However,
whether this is possible also depends on the kind and quan-
tity of medications taken. When specific quantities of barbi-
turate-containing or opioid medications are involved, with-
drawal may require hospitalization for close monitoring of
withdrawal symptoms and intravenous administration of
medications. The withdrawal of a significant amount of bar-
biturate-containing medications also requires a barbiturate
taper to prevent the occurrence of seizures. The withdrawal
of a significant amount of opioid medications requires
expertise in addiction medicine and may have to be done in
a detoxification center. Otherwise, it can often be accom-
plished on an outpatient basis, and several protocols have
been developed to assist the patient with the withdrawal.
A recent protocol employs sumatriptan for withdrawal
headache after abrupt discontinuation of the rebound-caus-
ing medications [17]. The sumatriptan is given in a dose of
25 mg orally, three times per day for 10 days, or until the
patient is headache-free for 24 hours. After that, it is only
used as needed for the abortive treatment of moderate and
severe headaches. Of the 35 sequentially selected patients to
be enrolled in a study using this particular protocol, nine left
the clinic and 26 were actually treated. They had suffered
from daily headaches for an average of 8.2 years. Of the 26
patients treated, 58% no longer experienced daily headaches
after 1 month, and 69% had reverted back to intermittent
headaches after 6 months.
Fig. 11 Example of
the increase in intake
of a caffeine contain-
ing analgesic medica-
tion for headache, in
number of tablets per
day, over a period of
10 years122
An out-patient protocol that I myself have used success-
fully for the last 20 years to withdraw patients with daily
headaches from the daily or almost daily use of abortive
medications is that utilizing a short course of prednisone.
Depending on the kind and quantity of the medications that
the patient has to be withdrawn from, I give prednisone for
3 or 6 days. The three-day schedule consists of 15 mg pred-
nisone four times per day for 1 day, 10 mg four times per
day for 1 day, and 5 mg four times per day for 1 day; the
days are doubled in the six-day schedule. If the patient
exhibits prominent muscular symptoms, that is, complains
of tight or sore neck and shoulder muscles, I add diazepam
to the schedule in a dose of 1–5 mg four times per day to
help relax the muscles.
I have used a similar schedule for patients admitted to
the hospital when outpatient withdrawal was unsuccessful
because of the patient’s inability to tolerate the withdrawal
headache or its association with severe nausea and vomiting.
Under these circumstances, I add metoclopramide as an
antinausea medication, which I give intravenously in a dose
of 10 mg four times per day. It is important to start the meto-
clopramide immediately, that is, before the patient becomes
sick, because once vomiting has developed, it is difficult to
control even with intravenous administration of the medica-
tion. Instead of prednisone orally, dexamethasone can be
given intravenously in a dose of 4 mg, four times per day,
for a number of consecutive days. The diazepam can then be
given every 6 hours but only as needed for severe headache
and can also be given intravenously. An alternative to
diazepam intravenously is lorazepam intramuscularly in a
dose of 1 or 2 mg, as needed every 6 hours.
An alternative to this in-patient protocol with metoclo-
pramide, dexamethasone, and diazepam or lorazepam is one
involving metoclopramide and dihydroergotamine. In this
protocol, both medications are given intravenously on a reg-
ular, generally 8-hour, schedule with the metoclopramide
administered before the dihydroergotamine. The administra-
tion sequence prevents the occurrence of nausea and vomit-
ing as a result of the intravenous administration of dihy-
droergotamine. The dose of metoclopramide is usually 10
mg, while that of dihydroergotamine is gradually increased
from 0.25 to 1 mg, depending on the ability of the patient to
tolerate the medication, especially in terms of gastrointesti-
nal side effects. Along-term follow-up study of 50 consecu-
tive patients with chronic daily headache treated with an
intravenous dihydroergotamine protocol showed 44% to
have good or excellent results after 3 months and 59% after
2 years [18].
After withdrawal from analgesic and vasoconstrictor
medications, headaches may improve for up to 3 months.
Often preventive pharmacologic treatment is initiated
immediately after the withdrawal but I generally do not do
that. An exception is when the patient has problems sleeping
at night for which I will prescribe amitriptyline, doxepin, or
trazodone. These are sedating tri- or tetracyclics of which
the first two have been shown to be effective in the preven-
tive treatment of chronic tension headache [19–22].
However, I do recommend that patients get involved imme-
diately with non-pharmacologic treatments, such as using a
heating pad daily on the neck and shoulders to help decrease
the muscle tightness that many of them have developed over
time. At a later stage, I may prescribe more formal physical
therapy, consisting of massage, ultrasound, stretching exer-
cises, etc. or do trigger point injections to further help relax
the muscles.
For the daily headaches, I allow patients to use muscle
relaxants such as metaxalone or carisoprodol. For the severe
headaches, 50-mg promethazine suppositories can be help-
ful, as long as it is judged better for the patient not to use
analgesic and vasoconstrictor medications. Once the
headaches have become intermittent, I focus with the
abortive treatment on the severe headaches for which I try to
find effective treatment, relying as much as possible on spe-
cific antimigraine medications. I define effective treatment
as treatment that provides full relief of headache and associ-
ated symptoms within 2 hours of initiation. It is important
for this treatment to be consistently effective as well, which
would allow the patient to wait until the headache is severe
before initiating it. This is the only way that patients can be
prevented from, over time, falling back into the pattern of
frequent intake of analgesic or vasoconstrictor medications.
With regard to preventive pharmacologic treatment, a
particularly useful combination in patients with frequent
and severe headaches is that of a tricyclic and a beta-block-
er [23]. The tricyclics that I prefer to use are amitriptyline,
doxepin, and imipramine. The first two I prescribe when
sedation is needed to help the patient fall asleep and sleep
through the night. If sleep is not an issue, I prefer
imipramine because it has fewer side effects, in particular
regarding increased appetite and weight gain. Imipramine
has also been shown to be effective in the preventive treat-
ment of chronic tension headache, but only in an open study
and with less benefit than amitriptyline [24].
With regard to the beta-blockers, six have been shown in
randomized, double-blind, placebo-controlled studies to be
effective in migraine prevention [25]. These beta-blockers
are: atenolol, bisoprolol, metoprolol, nadolol, propranolol,
and timolol. In patients with chronic daily headache, they
are often effective in decreasing the intensity of the
headaches, while the tricyclics tend to have more of an
effect on headache frequency. The calcium-entry blockers,
in particular verapamil [26, 27], I have found helpful if after
analgesic or vasoconstrictor withdrawal, the headaches con-
tinue to frequently wake the patient up out of sleep at night.
Kudrow [5] determined the effects of analgesic with-
drawal and preventive treatment with amitriptyline in 200123
patients with chronic muscle-contraction headache who
used analgesics daily, as documented by one-month pretrial
records. He randomly divided the patients into two groups
and four subgroups. Half of the patients were prescribed
amitriptyline (25 mg per day for 1 week and 50 mg per day
thereafter). In each group, half of the patients were allowed
to continue taking analgesics without restriction, while the
other half was instructed to discontinue these medications.
The percentage headache improvement he observed in the
four groups is shown in Table 6. Analgesic withdrawal, in
and by itself, resulted in a 43% headache improvement 1
month after initiation of treatment. The addition of
amitriptyline to the analgesic withdrawal increased the
headache improvement to 72%.
Our study suggests that, with the treatment approach
outlined above, two-thirds of patients who have daily
headaches can be improved to intermittent headaches [7].
Preventive treatment in these patients may make the inter-
mittent headaches somewhat better than what they were ini-
tially, as the shift from migraine to tension-type headaches
observed in the study suggests, when the present headaches
were compared to those that occurred initially.
However, what should be done with the patients who
continue to have frequent and severe headaches, despite
being off analgesic and vasoconstrictor medications and
despite efforts at preventive treatment? It is impossible to let
these patients suffer forever and, here, there may be an indi-
cation for the use of long-acting opioids, to relieve the pain
and allow these patients to function in their professional and
personal lives. The long-acting opioids that I have used in
these patients are fentanyl patch, oxycodone, and morphine
sulfate. I have found that the medications generally work
shorter than the manufacturers indicate and, for example,
will use the fentanyl patch every 2 days rather than 3 days.
I gradually increase the dose of the medication until satis-
factory pain control is achieved and the patient is back to a
relatively normal level of functioning. I prefer the use of
long-acting to short-acting opioids because of much less
development of tolerance and addiction. For some reason,
rebound headache does not seem to develop with the long-
acting opioids, while it is standard to occur with short-acting
analgesics, including opioids. The development of tolerance
and rebound headache both increase the use of opioid anal-
gesics over time and make it difficult, if not impossible, to
accomplish adequate pain control.
Hemicrania continua
As far as its presentation is concerned, hemicrania continua
[28] can be looked upon as a form of chronic daily
headache. It is a non-paroxysmal daily headache, present
continuously throughout the day, limited to one side of the
head. However, it is different from chronic daily headache in
its treatment. Hemicrania continua is treated with
indomethacin to which it has an absolute response, similar
to paroxysmal hemicrania [29]. The different treatment sug-
gests a different etiology, which would preclude the condi-
tion from being grouped with chronic daily headache.
Hemicrania continua has been described resistant to
preventive treatment with indomethacin [30]. Resistance to
treatment with indomethacin, however, by definition
means that it is not hemicrania continua. This does not
mean that there are not many patients who have continuous
unilateral headaches with fixed lateralization that do not
respond preventively to indomethacin. These patients have
chronic daily headache and should be treated accordingly.
The key to look for in the history is a response to aspirin,
which seems to predict the responsiveness of the
headaches to indomethacin. This is also the feature that led
to the identification of both paroxysmal hemicrania and
hemicrania continua as indomethacin-responsive headache
syndromes.
Table 6 Headache improvement 1 month after initiation of treat-
ment in 200 patients with chronic muscle-contraction headache




Analgesics continued (n=50) 30
Analgesics withdrawn (n=50) 72
Not treated with amitriptyline
Analgesics continued (n=50) 18
Analgesics withdrawn (n=50) 43
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